289 related articles for article (PubMed ID: 34374773)
1. Association of Diphtheria-Tetanus-Acellular Pertussis Vaccine Timeliness and Number of Doses With Age-Specific Pertussis Risk in Infants and Young Children.
Rane MS; Rohani P; Halloran ME
JAMA Netw Open; 2021 Aug; 4(8):e2119118. PubMed ID: 34374773
[TBL] [Abstract][Full Text] [Related]
2. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
3. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.
Glanz JM; Narwaney KJ; Newcomer SR; Daley MF; Hambidge SJ; Rowhani-Rahbar A; Lee GM; Nelson JC; Naleway AL; Nordin JD; Lugg MM; Weintraub ES
JAMA Pediatr; 2013 Nov; 167(11):1060-4. PubMed ID: 24019039
[TBL] [Abstract][Full Text] [Related]
4. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
5. Undervaccination with diphtheria, tetanus, and pertussis vaccine: National trends and association with pertussis risk in young children.
Huang WT; Lin HC; Yang CH
Hum Vaccin Immunother; 2017 Apr; 13(4):757-761. PubMed ID: 27858500
[TBL] [Abstract][Full Text] [Related]
6. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.
Misegades LK; Winter K; Harriman K; Talarico J; Messonnier NE; Clark TA; Martin SW
JAMA; 2012 Nov; 308(20):2126-32. PubMed ID: 23188029
[TBL] [Abstract][Full Text] [Related]
7. Association between pertussis vaccination coverage and other sociodemographic factors and pertussis incidence using surveillance data.
Rane MS; Wakefield J; Rohani P; Halloran ME
Epidemics; 2023 Sep; 44():100689. PubMed ID: 37295130
[TBL] [Abstract][Full Text] [Related]
8. Estimating Population-Level Effects of the Acellular Pertussis Vaccine Using Routinely Collected Immunization Data.
Rane MS; Halloran ME
Clin Infect Dis; 2021 Dec; 73(11):2101-2107. PubMed ID: 33881527
[TBL] [Abstract][Full Text] [Related]
9. Acellular Pertussis Vaccine Effectiveness Over Time.
Zerbo O; Bartlett J; Goddard K; Fireman B; Lewis E; Klein NP
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31182549
[TBL] [Abstract][Full Text] [Related]
10. Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children.
Domenech de Cellès M; Rohani P; King AA
JAMA Pediatr; 2019 Jun; 173(6):588-594. PubMed ID: 31009031
[TBL] [Abstract][Full Text] [Related]
11. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak.
Bronson-Lowe D; Anderson SM
Arch Pediatr Adolesc Med; 2009 May; 163(5):417-21. PubMed ID: 19414686
[TBL] [Abstract][Full Text] [Related]
12. Pertussis in infants under one year old: risk markers and vaccination status--a case-control study.
Zamir CS; Dahan DB; Shoob H
Vaccine; 2015 Apr; 33(17):2073-8. PubMed ID: 25728322
[TBL] [Abstract][Full Text] [Related]
13. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
[TBL] [Abstract][Full Text] [Related]
14. DTaP combination vaccine use and adherence: A retrospective cohort study.
Loiacono MM; Pool V; van Aalst R
Vaccine; 2021 Feb; 39(7):1064-1071. PubMed ID: 33483215
[TBL] [Abstract][Full Text] [Related]
15. Duration of protection after first dose of acellular pertussis vaccine in infants.
Quinn HE; Snelling TL; Macartney KK; McIntyre PB
Pediatrics; 2014 Mar; 133(3):e513-9. PubMed ID: 24515514
[TBL] [Abstract][Full Text] [Related]
16. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
[TBL] [Abstract][Full Text] [Related]
17. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
18. Waning immunity to pertussis following 5 doses of DTaP.
Tartof SY; Lewis M; Kenyon C; White K; Osborn A; Liko J; Zell E; Martin S; Messonnier NE; Clark TA; Skoff TH
Pediatrics; 2013 Apr; 131(4):e1047-52. PubMed ID: 23478868
[TBL] [Abstract][Full Text] [Related]
19. Mixing of diphtheria, tetanus, and acellular pertussis (DTaP) vaccines in a population of children in managed care.
Masseria C; Buikema AR; Liu F; Krishnarajah G
Hum Vaccin Immunother; 2015; 11(5):1175-83. PubMed ID: 25714800
[TBL] [Abstract][Full Text] [Related]
20. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
